LAGUNA HILLS, Calif., Nov. 12, 2020 /PRNewswire/ -- Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced that it has closed a $42.5 million Series E equity financing. Proceeds from the financing will be used to support [...]
LAGUNA HILLS, Calif., August 3, 2020 /PRNewswire/ --Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AFib) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced successful pre-clinical results demonstrating their existing cryoablation catheter is also capable of ablating the tissue through pulsed field ablation (PFA) delivered [...]
LAGUNA HILLS, Calif., June 1, 2019 /PRNewswire/ --Adagio Medical, Inc., announces that it has received CE Mark approval for its ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) for the endocardial treatment of paroxysmal (PAF) and persistent (PsAF) atrial fibrillation and atrial flutter. "More than half of all atrial fibrillation (AF) patients are diagnosed with PsAF. There [...]
LAGUNA HILLS, Calif., Dec. 16, 2019 /PRNewswire/ -- Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial. The FDA approved study aims to evaluate the safety and efficacy of Adagio's ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) in the treatment of persistent atrial fibrillation (PsAF). Data [...]
LAGUNA HILLS, Calif., Aug. 19, 2019 /PRNewswire/ -- Adagio Medical, Inc. (Adagio), the developer of iCLAS™, the company's ultra-low temperature intelligent continuous lesion ablation system, announced that it has received an Investigational Device Exemption approval with conditions from the US Food and Drug Administration (FDA) to conduct a non-randomized, single-arm clinical study for persistent atrial fibrillation (AF). [...]
LAGUNA HILLS, Calif., July 31, 2019 /PRNewswire/ -- Adagio Medical, Inc., the developer of iCLAS™, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces that the first PsAF patient was successfully treated with its new One Shot+™ cryoablation catheter in a procedure that utilizes only anatomical markers with limited [...]
LAGUNA HILLS, Calif., Nov. 28, 2018 /PRNewswire/ -- Adagio Medical, Inc., developer of the iCLAS™ technology, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces updates to its ongoing cryoablation study for Persistent Atrial Fibrillation (PsAF). The study is currently being conducted at two clinical sites in Europe and two [...]
Multiple Transmural, Continuous and Durable Lesions Created in Both Atria LAGUNA HILLS, Calif., Oct. 4, 2018 /PRNewswire/ -- Adagio Medical, Inc., the developer of the iCLAS™ technology, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces the successful completion of its chronic atrial fibrillation animal study, performed in collaboration [...]
Simplified Procedure for Achieving Pulmonary Vein Isolation (PVI) with a Single Continuous Transmural Lesion LAGUNA HILLS, Calif., Oct. 1, 2018 /PRNewswire/ -- Adagio Medical, Inc., the developer of the iCLAS™ technology, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces that the first patients were successfully treated with its new [...]
LAGUNA HILLS, Calif., May 9, 2017 /PRNewswire/ -- Adagio Medical, Inc., the developer of a cryolinear ablation technology platform for the treatment of cardiac arrhythmias, announces that the first three persistent atrial fibrillation patients were treated in May 2017 using its technology. This milestone follows the successful treatment of more than 25 arrhythmia patients in the [...]